CAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Fontan Circulation, Single Ventricle Heart Disease, HFpEF - Heart Failure With Preserved Ejection Fraction

In brief

The purpose of this research is to determine whether treatment with the study drug dapagliflozin for 3 months affects peripheral venous pressure at rest and during exercise in adults with failing Fontan circulation.

Key facts

Study ID

NCT06762964

Run by

Mayo Clinic

People needed

27

Starts

2025-05-16

Expected to finish

2027-02-01

Last updated by the study team

2026-05-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Signed informed consent prior to any study specific procedures
• History of Fontan procedure
• Male or female subject
• Age ≥ 18
• Symptoms of dyspnea (NYHA II-IV) with no non-cardiac or ischemia explanation
• Elevated peripheral venous pressure (PVP) at rest or during exercise (≥20 mmHg) ascertained at Visit 1. Patients that have consented to study procedures but do not meet this invasive criterion will be considered as screen failures and will not be randomized.

You may not qualify if…

• Type I diabetes
• Any of the following medications: Insulin or Pramlintide, Sandostatin, Akeega (abiraterone acetate), Growth Hormone (Somatogrogon-GHLA), Lithium, Chloroquine, Hydroxychloroquine, Thioctic acid (alpha lipoic acid), Empagliflozin or Canagliflozin
• Recent hospitalization (<30 days) or revascularization (<90 days)
• Significant valvular heart disease (≥moderate stenosis, >moderate regurgitation)
• Significant Fontan obstruction with resting SVC-IVC gradient >4 mmHg
• Primary cardiomyopathy (such as amyloid)
• Dyspnea due to primary lung disease or myocardial ischemia in the opinion of the investigator
• Severe anemia (hemoglobin <9 gm/dl)
• Severe kidney disease (estimated GFR<30) or liver disease
• Women of childbearing potential not willing to use a medically accepted method of contraception OR who are currently pregnant (confirmed with positive pregnancy test) or breast feeding.
• History of serious hypersensitivity reaction to dapagliflozin
• Subjects on dialysis
• Subjects with severe liver disease with history of decompensation including ascites or encephalopathy or variceal bleeding
• Single ventricle heart disease without Fontan palliation
• Those with a history of Fontan takedown

Where it is running

• Mayo Clinic — Rochester, Minnesota, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.